162 related articles for article (PubMed ID: 30962244)
1. Identification of potential carcinogenic and chemopreventive effects of prescription drugs: a protocol for a Norwegian registry-based study.
Andreassen BK; Støer NC; Martinsen JI; Ursin G; Weiderpass E; Thoresen GH; Debernard KB; Karlstad Ø; Pottegard A; Friis S
BMJ Open; 2019 Apr; 9(4):e028504. PubMed ID: 30962244
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular, antidepressant and immunosuppressive drug use in relation to risk of cutaneous melanoma: a protocol for a prospective case-control study.
Berge LAM; Andreassen BK; Stenehjem JS; Larsen IK; Furu K; Juzeniene A; Roscher I; Heir T; Green A; Veierød MB; Robsahm TE
BMJ Open; 2019 Feb; 9(2):e025246. PubMed ID: 30787091
[TBL] [Abstract][Full Text] [Related]
3. Injury Prevention and long-term Outcomes following Trauma-the IPOT project: a protocol for prospective nationwide registry-based studies in Norway.
Stenehjem JS; Røise O; Nordseth T; Clausen T; Natvig B; O Skurtveit S; Eken T; Kristiansen T; Gran JM; Rosseland LA
BMJ Open; 2021 May; 11(5):e046954. PubMed ID: 34006552
[TBL] [Abstract][Full Text] [Related]
4. Drugs with potential chemopreventive properties in relation to epithelial ovarian cancer--a nationwide case-control study.
Baandrup L
Dan Med J; 2015 Jul; 62(7):. PubMed ID: 26183052
[TBL] [Abstract][Full Text] [Related]
5. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
6. Postmarketing surveillance of potentially fatal reactions to oncology drugs: potential utility of two signal-detection algorithms.
Hauben M; Reich L; Chung S
Eur J Clin Pharmacol; 2004 Dec; 60(10):747-50. PubMed ID: 15619136
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D, obesity and leptin in relation to bladder cancer incidence and survival: prospective protocol study.
Gislefoss RE; Stenehjem JS; Hektoen HH; Andreassen BK; Langseth H; Axcrona K; Weiderpass E; Mondul A; Robsahm TE
BMJ Open; 2018 Mar; 8(3):e019309. PubMed ID: 29602840
[TBL] [Abstract][Full Text] [Related]
8. Drug safety data mining with a tree-based scan statistic.
Kulldorff M; Dashevsky I; Avery TR; Chan AK; Davis RL; Graham D; Platt R; Andrade SE; Boudreau D; Gunter MJ; Herrinton LJ; Pawloski PA; Raebel MA; Roblin D; Brown JS
Pharmacoepidemiol Drug Saf; 2013 May; 22(5):517-23. PubMed ID: 23512870
[TBL] [Abstract][Full Text] [Related]
9. The value of a health insurance database to conduct pharmacoepidemiological studies in oncology.
Conte C; Vaysse C; Bosco P; Noize P; Fourrier-Reglat A; Despas F; Lapeyre-Mestre M
Therapie; 2019 Apr; 74(2):279-288. PubMed ID: 30824175
[TBL] [Abstract][Full Text] [Related]
10. Safety profile of celecoxib as used in general practice in England: results of a prescription-event monitoring study.
Layton D; Wilton LV; Shakir SA
Eur J Clin Pharmacol; 2004 Sep; 60(7):489-501. PubMed ID: 15278327
[TBL] [Abstract][Full Text] [Related]
11. Use and overuse of sumatriptan. Pharmacoepidemiological studies based on prescription register and interview data.
Gaist D
Cephalalgia; 1999 Oct; 19(8):735-61. PubMed ID: 10570730
[TBL] [Abstract][Full Text] [Related]
12. Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria.
Shakir SA; Layton D
Drug Saf; 2002; 25(6):467-71. PubMed ID: 12071785
[TBL] [Abstract][Full Text] [Related]
13. Record linkage for pharmacoepidemiological studies in cancer patients.
Herk-Sukel MP; Lemmens VE; Poll-Franse LV; Herings RM; Coebergh JW
Pharmacoepidemiol Drug Saf; 2012 Jan; 21(1):94-103. PubMed ID: 21812067
[TBL] [Abstract][Full Text] [Related]
14. Use of health care databases in pharmacoepidemiology.
Hennessy S
Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):311-3. PubMed ID: 16611207
[TBL] [Abstract][Full Text] [Related]
15. The Nordic prescription databases as a resource for pharmacoepidemiological research--a literature review.
Wettermark B; Zoëga H; Furu K; Korhonen M; Hallas J; Nørgaard M; Almarsdottir A; Andersen M; Andersson Sundell K; Bergman U; Helin-Salmivaara A; Hoffmann M; Kieler H; Martikainen J; Mortensen M; Petzold M; Wallach-Kildemoes H; Wallin C; Sørensen H
Pharmacoepidemiol Drug Saf; 2013 Jul; 22(7):691-9. PubMed ID: 23703712
[TBL] [Abstract][Full Text] [Related]
16. What is pharmacoepidemiology? Definition, methods, interest and clinical applications.
Montastruc JL; Benevent J; Montastruc F; Bagheri H; Despas F; Lapeyre-Mestre M; Sommet A
Therapie; 2019 Apr; 74(2):169-174. PubMed ID: 30389102
[TBL] [Abstract][Full Text] [Related]
17. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
18. Does Angiotensin-Converting Enzyme Inhibitor and β-Blocker Use Reduce the Risk of Primary Liver Cancer? A Case-Control Study Using the U.K. Clinical Practice Research Datalink.
Hagberg KW; Sahasrabuddhe VV; McGlynn KA; Jick SS
Pharmacotherapy; 2016 Feb; 36(2):187-95. PubMed ID: 26846893
[TBL] [Abstract][Full Text] [Related]
19. Use of Immunomodulating Drugs and Risk of Cutaneous Melanoma: A Nationwide Nested Case-Control Study.
Berge LAM; Andreassen BK; Stenehjem JS; Heir T; Karlstad Ø; Juzeniene A; Ghiasvand R; Larsen IK; Green AC; Veierød MB; Robsahm TE
Clin Epidemiol; 2020; 12():1389-1401. PubMed ID: 33376408
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
